Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of our Company at their meeting held ....
MEDICO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Medico Remedies Ltd reported strong full-year FY26 results with total income of Rs 20,231 lakhs, up 33% from Rs 15,363 lakhs in FY25. Revenue from operations grew to Rs 20,638 lakhs from Rs 15,094 lakhs. Net profit increased 30% to Rs 1,313 lakhs from Rs 1,009 lakhs. Basic EPS improved to Rs 1.58 from Rs 1.22. The company is export-focused with exports of Rs 5,364 lakhs vs domestic sales of just Rs 274 lakhs in Q4. Trade receivables rose significantly to Rs 8,199 lakhs from Rs 5,718 lakhs, and inventories increased to Rs 3,002 lakhs, indicating higher sales activity. Statutory auditors Shah Shroff & Associates issued an unmodified audit opinion confirming clean financials.
The company delivered solid 30% profit growth driven by strong export revenue, which should be positive for the stock. The significant rise in trade receivables warrants monitoring as it could indicate extended credit terms to buyers. Overall financial health appears stable with increased equity base.